Nazzareno Galie

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi request reprint Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Drugs 68:1049-66. 2008
  2. doi request reprint Tadalafil therapy for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Circulation 119:2894-903. 2009
  3. doi request reprint Updated treatment algorithm of pulmonary arterial hypertension
    Nazzareno Galie
    Department of Experimental, Diagnostic and Specialty Medicine DIMES, Bologna University Hospital, Bologna, Italy Electronic address
    J Am Coll Cardiol 62:D60-72. 2013
  4. doi request reprint Developing a heart score: next steps
    Nazzereno Galiè
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Am J Cardiol 110:49S-51S. 2012
  5. pmc A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Eur Heart J 30:394-403. 2009
  6. ncbi request reprint Current therapeutic approaches to pulmonary arterial hypertension
    Nazzareno Galie
    Instituto de Cardiologia, Universidad de Bolonia, Bolonia, Italia
    Rev Esp Cardiol 63:708-24. 2010
  7. doi request reprint Clinical worsening in trials of pulmonary arterial hypertension: results and implications
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Curr Opin Pulm Med 16:S11-9. 2010
  8. ncbi request reprint Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study
    Nazzareno Galie
    Istituto di Cardiologia, Universita di Bologna, Via Massarenti, 9 IT 40138, Bologna, Italy
    Circulation 114:48-54. 2006
  9. ncbi request reprint Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy and Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California, USA
    Proc Am Thorac Soc 3:571-6. 2006
  10. ncbi request reprint Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Circulation 117:3010-9. 2008

Detail Information

Publications53

  1. ncbi request reprint Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Drugs 68:1049-66. 2008
    ..A treatment algorithm based on the one used in the treatment of PAH patients is proposed for patients with PAH associated with corrected and uncorrected congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome...
  2. doi request reprint Tadalafil therapy for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Circulation 119:2894-903. 2009
    ..Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway...
  3. doi request reprint Updated treatment algorithm of pulmonary arterial hypertension
    Nazzareno Galie
    Department of Experimental, Diagnostic and Specialty Medicine DIMES, Bologna University Hospital, Bologna, Italy Electronic address
    J Am Coll Cardiol 62:D60-72. 2013
    ..The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments. ..
  4. doi request reprint Developing a heart score: next steps
    Nazzereno Galiè
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Am J Cardiol 110:49S-51S. 2012
    ..This shortlist is the starting point for developing a score that reflects heart function; such a score could have potential in the future clinical management of patients with PAH...
  5. pmc A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Eur Heart J 30:394-403. 2009
    ..We performed a meta-analysis of all randomized controlled trials with drugs published in this condition...
  6. ncbi request reprint Current therapeutic approaches to pulmonary arterial hypertension
    Nazzareno Galie
    Instituto de Cardiologia, Universidad de Bolonia, Bolonia, Italia
    Rev Esp Cardiol 63:708-24. 2010
    ..However, drugs intended specifically for the treatment of pulmonary arterial hypertension may be considered in inoperable cases or after suboptimal surgery...
  7. doi request reprint Clinical worsening in trials of pulmonary arterial hypertension: results and implications
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Curr Opin Pulm Med 16:S11-9. 2010
    ....
  8. ncbi request reprint Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study
    Nazzareno Galie
    Istituto di Cardiologia, Universita di Bologna, Via Massarenti, 9 IT 40138, Bologna, Italy
    Circulation 114:48-54. 2006
    ..Theoretically, interventions that have some effect on the systemic vascular bed could worsen the shunt and increase hypoxemia...
  9. ncbi request reprint Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy and Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California, USA
    Proc Am Thorac Soc 3:571-6. 2006
    ....
  10. ncbi request reprint Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Circulation 117:3010-9. 2008
    ..Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension...
  11. ncbi request reprint Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
    N Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Lancet 371:2093-100. 2008
    ..This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan in patients with WHO FC II pulmonary arterial hypertension...
  12. doi request reprint Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension
    Ronald J Oudiz
    LA Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA
    J Am Coll Cardiol 54:1971-81. 2009
    ..This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH)...
  13. ncbi request reprint Ambrisentan therapy for pulmonary arterial hypertension
    Nazzareno Galie
    University of Bologna, Bologna, Italy
    J Am Coll Cardiol 46:529-35. 2005
    ..The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH)...
  14. ncbi request reprint [Pulmonary arterial hypertension. Part II: Medical and surgical treatment]
    Alessandra Manes
    Centro di Diagnosi e Terapia dell Ipertensione Polmonare, Istituto di Cardiologia, Azienda Ospedaliero Universitaria, Bologna
    G Ital Cardiol (Rome) 10:366-81. 2009
    ..As available treatments do not constitute a cure for pulmonary arterial hypertension, further progresses are expected in the near future...
  15. ncbi request reprint Pulmonary arterial hypertension in the pediatric age
    Andrea Donti
    Pediatric Cardiology, Policlinico S Orsola Malpighi, University of Bologna, Italy
    J Cardiovasc Med (Hagerstown) 8:72-7. 2007
    ....
  16. ncbi request reprint Emerging medical therapies for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    Prog Cardiovasc Dis 45:213-24. 2002
    ....
  17. ncbi request reprint Sildenafil citrate therapy for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    N Engl J Med 353:2148-57. 2005
    ....
  18. doi request reprint Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study
    Lewis J Rubin
    Department of Medicine, University of California at San Diego, UCSD Medical Center Thornton, 9300 Campus Point Dr MC 7372, La Jolla, CA 92037, USA
    Chest 140:1274-83. 2011
    ..The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed...
  19. ncbi request reprint [Pulmonary arterial hypertension. Part I: pathobiologic, pathophysiologic, clinical and diagnostic aspects]
    Massimiliano Palazzini
    Centro di Diagnosi e Terapia dell Ipertensione Polmonare, Istituto di Cardiologia, Azienda Ospedaliero Universitaria, Bologna
    G Ital Cardiol (Rome) 10:271-300. 2009
    ..Evaluation of vasoreactivity and assessment of the severity of functional and hemodynamic changes are also required in pulmonary arterial hypertension for an appropriate therapeutic decision-making and estimate of results...
  20. ncbi request reprint [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    Rev Esp Cardiol 58:523-66. 2005
  21. ncbi request reprint The study of risk in pulmonary arterial hypertension
    Lewis J Rubin
    School of Medicine, University of California San Diego, La Jolla, CA 92093, USA
    Eur Respir Rev 21:234-8. 2012
    ..Herein, we discuss the impact of this information on three key areas: 1) clinical decision-making; 2) policy and reimbursement; and 3) future trials and research...
  22. ncbi request reprint Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses
    Lewis J Rubin
    University of California, San Diego, CA, USA
    Proc Am Thorac Soc 3:601-7. 2006
    ..Continued research and clinical trials investigating possible applications of new medical treatments are required...
  23. ncbi request reprint Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    J Am Coll Cardiol 41:1380-6. 2003
    ..The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH)...
  24. ncbi request reprint Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells
    Benedetta Tantini
    Department of Biochemistry, G Moruzzi University of Bologna, Bologna, Italy
    Basic Res Cardiol 100:131-8. 2005
    ..We conclude that sildenafil exerts an antiproliferative effect on human PASMC that is mediated by an interaction between the cGMP-PKG and the cAMP-PKA activated pathways, leading to inhibition of PDGF-mediated activation of the ERK...
  25. ncbi request reprint Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    J Am Coll Cardiol 39:1496-502. 2002
    ....
  26. ncbi request reprint Pulmonary arterial hypertension: therapeutic algorithm
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Ital Heart J 6:856-60. 2005
    ..Combination therapy can be attempted in selected cases. Balloon atrial septostomy and/or lung transplantation are indicated for refractory patients or when medical treatments are unavailable...
  27. doi request reprint Pulmonary artery intimal sarcoma. Problems in the differential diagnosis
    Domenico Attinà
    U O Radiologia, Dipartimento Cardio Toraco Vascolare, Azienda Ospedaliero universitaria S Orsola Malpighi, Via Massarenti 9, 40128, Bologna, Italy
    Radiol Med 118:1259-68. 2013
    ....
  28. ncbi request reprint Prostanoids for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Am J Respir Med 2:123-37. 2003
    ....
  29. ncbi request reprint Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    J Am Coll Cardiol 43:81S-88S. 2004
    ..Combination therapy can be attempted in selected cases. Both balloon atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable...
  30. ncbi request reprint The endothelin system in pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, via Massarent 9, 40138 Bologna, Italy
    Cardiovasc Res 61:227-37. 2004
    ..Additional trials with these drugs are currently ongoing. In conclusion, the hypothesis that the ET-1 system over-activation can be successfully antagonised in patients with PAH has been clearly demonstrated...
  31. ncbi request reprint Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure
    Francesco Grigioni
    Cardiology Institute, University of Bologna, Bologna, Italy
    J Heart Lung Transplant 25:1241-6. 2006
    ..It is unknown whether time-related changes of pulmonary hypertension (PH) have prognostic relevance in severe chronic heart failure (CHF)...
  32. doi request reprint Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups
    Alessandra Manes
    Institute of Cardiology, Bologna University Hospital, Via Massarenti 9, Bologna 40138, Italy
    Eur Heart J 35:716-24. 2014
    ....
  33. doi request reprint Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography
    Maurizio Zompatori
    Department of Radiology, Ospedale Sant Orsola, Bologna, Italy
    Radiol Med 118:1360-72. 2013
    ..In addition, we assessed the role of high-resolution computed tomography (HRCT) in the diagnostic and therapeutic pathway for such patients...
  34. doi request reprint Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients
    Cecilia Modolon
    Department of Cardio Thoracic Vascular, Division of Cardio Thoracic Radiology, Policlinico S Orsola Malpighi, Via Massarenti 9, 40100 Bologna, Italy
    Eur Radiol 22:1059-66. 2012
    ....
  35. ncbi request reprint Evaluation of pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    Curr Opin Cardiol 19:575-81. 2004
    ..The purpose of this review is to analyze the current knowledge of the evaluation of PAH patients...
  36. doi request reprint The use of combination therapy in pulmonary arterial hypertension: new developments
    N Galie
    Institute of Cardiology, University of Bologna, Italy
    Eur Respir Rev 18:148-53. 2009
    ..Monitoring should be performed regularly and be based on repeatable, noninvasive, measurable parameters that have prognostic value...
  37. doi request reprint Current therapeutic approaches to pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Rev Esp Cardiol (Engl Ed) 63:708-24. 2010
    ..However, drugs intended specifically for the treatment of pulmonary arterial hypertension may be considered in inoperable cases or after suboptimal surgery. ..
  38. doi request reprint Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition
    Silvia Cantoni
    Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems, Bologna, Italy
    FEBS J 280:2042-55. 2013
    ..These findings may provide novel perspectives on the use of histone deacetylase inhibitors in PAH...
  39. ncbi request reprint Pulmonary arterial hypertension: a look to the future
    Lewis J Rubin
    Pulmonary Vascular Center, University of California San Diego School of Medicine, La Jolla, California, USA
    J Am Coll Cardiol 43:89S-90S. 2004
    ..This summary provides a brief overview of future directions in the field...
  40. ncbi request reprint Transcatheter aortic valve implantation for severe autograft regurgitation after Ross operation
    Francesco Saia
    Institute of Cardiology, University of Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    EuroIntervention 10:141-5. 2014
    ..The procedure was successful and the in-hospital course was uncomplicated. During follow-up, pulmonary pressure and resistances were significantly lowered and at four years the patient showed markedly improved exercise tolerance. ..
  41. ncbi request reprint Acute hand ischemia after radial intervention in patient with CREST-associated pulmonary hypertension: successful treatment with manual thromboaspiration
    Nevio Taglieri
    Institute of Cardiology, Bologna University, St Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy
    J Invasive Cardiol 25:89-91. 2013
    ..This case shows that radial occlusion, one of the most common and usually asymptomatic complications following transradial cardiac catheterization, may cause severe hand ischemia in patients with small-vessel inflammatory disease...
  42. ncbi request reprint Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest?
    Piero Maria Mikus
    Heart and Lung Transplantation Program, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti n 9, Bologna, Italy
    Eur J Cardiothorac Surg 30:563-5. 2006
    ..The initial encouraging results have convinced us to apply systematically this technique in the cases operated in our center, even though further investigations are necessary to fully examine this technique...
  43. doi request reprint Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality?
    Maurice Beghetti
    Pediatric Cardiology Unit, Department of the Child and Adolescent, Children s University Hospital, 6 Rue Willy Donze, Geneva, Switzerland
    Congenit Heart Dis 7:3-11. 2012
    ....
  44. ncbi request reprint Pulmonary arterial hypertension associated to connective tissue diseases
    N Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Lupus 14:713-7. 2005
    ..Also, the endothelin receptor antagonists bosentan and sitaxentan, the phosphodyesterase-type-5 sildenafil and subcutaneous treprostinil have shown favourable results...
  45. ncbi request reprint Bosentan therapy for pulmonary arterial hypertension
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California at San Diego, La Jolla 92037 1330, USA
    N Engl J Med 346:896-903. 2002
    ..The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses...
  46. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  47. ncbi request reprint Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  48. ncbi request reprint Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Robyn J Barst
    Department of Pediatrics, Columbia University Medical Center, New York, New York, USA
    J Am Coll Cardiol 47:2049-56. 2006
    ..We sought to determine the optimal dose of the selective endothelin A (ET(A)) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included...
  49. ncbi request reprint Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Cardiovasc Pharmacol 49:1-5. 2007
    ..Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol...
  50. doi request reprint Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival
    Raymond L Benza
    University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
    Chest 134:775-82. 2008
    ..Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study...
  51. ncbi request reprint BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension
    Micheala A Aldred
    Division of Medical Genetics, Dept of Genetics, University of Leicester, Leicester, United Kingdom
    Hum Mutat 27:212-3. 2006
    ..Dosage analysis should now be considered an integral of part of the molecular work-up of PAH patients...
  52. ncbi request reprint Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension
    Rajiv D Machado
    Division of Medical Genetics, Department of Genetics, University of Leicester, Leicester, United Kingdom
    Hum Mutat 27:121-32. 2006
    ....